Skip to main content

Table 4 Comparison of c indices and bootstrap confidence intervals of VENUSS score, VENUSS group, UISS, TNM and Leibovich group in predicting recurrence at 1, 2 and 5 years

From: The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort

Cohort

Model

1 year

2 years

5 years

Development

VENUSS score

91.4 (85.5–95.0)

87.2 (83.8–90.7)

83.9 (78.7–88.6)

 

VENUSS group

89.8 (84.4–93.5)

84.2 (79.5–88.7)

81.1 (75.5–86.5)

UISS

88.6 (83.7–92.7)

82.9 (78.2–87.7)

79.3 (73.8–84.5)

TNM

83.7 (78.4–88.4)

78.2 (72.8–82.6)

75.9 (70.8–80.4)

2018 Leibovich group

78.7 (72.7–85.4)

78.2 (72.0–82.3)

76.5 (70.9–81.0)

ASSURE

VENUSS score

73.2 (64.5–80.4)

68.3 (61.3–76.1)

66.5 (60.5–73.7)

 

VENUSS group

66.9 (58.7–74.0)

64.9 (59.6–70.8)

64.6 (57.8–69.8)

UISS

64.2 (55.3–71.5)

63.7 (58.0–69.2)

62.5 (56.8–67.3)

TNM

62.0 (54.0–69.3)

59.7 (53.8–66.6)

60.2 (53.9–65.8)

2018 Leibovich group

61.3 (51.6–67.9)

60.0 (52.3–63.8)

58.2 (50.2–62.7)